EMA
EUROPEAN MEDICINES AGENCY

Dosage review and adjustment of selected veterinary antibiotics

(ADRA project)

Johan Schefferlie

Chair of EMA's Committee for Veterinary Medicinal Products (CVMP)

Table of contents

Background



CVMP Reflection paper: What can *WE* do to refine dosages in the PI?

CVMP reflection paper – proposed methodology

PK/PD modelling to establish a refined **dose**

PK modelling for adjustment of **withdrawal periods**

Stepwise data review approach to address:

target animal safety, environmental risk assessment, treatment duration



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

12 January 2021
EMA/CVMP/849775/2017
Committee for Medicinal Products for Veterinary Use (CVMP)

Reflection paper on dose review and adjustment of established veterinary antibiotics in the context of SPC harmonisation

Adopted by CVMP for release for consultation	19 July 2018
Start of public consultation	27 July 2018
End of consultation (deadline for comments)	31 January 2019
Adopted by CVMP	10 December 2020

Keywords	antimicrobial resistance (AMR), summary of product characteristics (SPC), Dose review and adjustment, pharmacokinetic/pharmacodynamic (PK/PD) modelling, target animal safety (TAS), withdrawal periods (WP) and the environmental risk assessment (ERA)

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000
An agency of the European Union



CVMP reflection paper on dose review and adjustment of established veterinary antibiotics in the context of SPC harmonisation: Recommendations

Slido: #ADRAproject

ADRA project

- **Project goals**
- **Preparation phase**
- **Assessment under Art. 141(1)(i)**
- **Project limitations**
- **Stakeholders' interaction**
- **Phasing of activities**

Project goals

Minimise occurrence of resistance, safeguarding availability of first-line treatment veterinary antibiotics in EU, **ensuring efficacy and safety** when used according to the product information (PI)

Refined dosages in PI of VMPs will further ensure **prudent use of antibiotics** in veterinary medicines.

Review should **not lead to loss of VMPs or indications**

Preparation phase

ADRA working group formed by CVMP/CMDv/WP members *(2024)*

Questionnaire sent to national competent authorities and industry stakeholders *(2024)*

Priority list of antimicrobial candidate substances adopted *(February 2025)*



Industry info session *(22 May 2025)*

Priority list of antimicrobial candidate substances

Step 1 – NCAs answers

:Most cited animal species

1. ***Pig***
2. ***Cattle***
3. *Dog (far below)*



Top 5 cited substances

1. *Amoxicillin*
2. *Oxytetracycline*
3. *Tiamulin*
4. *Tylosin*
5. *Doxycyclin*

Top 5 cited susbtances

1. *Amoxicillin*
2. *Benzylpenicilline*
3. *Oxytetracycline*
4. *Colistin*
5. *Tylosin*

After priorisation at step 2 – Sales data and RoA –

Step 2 – Sales data and RoA

From ESVAC data

Most sold antibiotic as « oral solution »

1. **Amoxicillin**
2. **Doxycycline**
3. **Tylosin**
4. **Lincomycin**
5. **Oxytetracycline**

1. *Amoxicillin*
2. *Oxytetracycline*
3. *Tylosin*
4. *Doxycyclin*
5. *Tiamulin*

No fixed combination VMPs

1. *Amoxicillin*
2. *Oxytetracycline*
3. *Tylosin*
4. *Benzylpenicilline*
5. *Colistin*

Oral route only

Assessment under Art. 141(1)(i)

Scientific advice

CVMP to provide advice on the **use of antimicrobials** in animals to **minimise the occurrence** of **resistance** in EU



Experts' consultation

PK/PD modelling, efficacy of antibiotics, TAS, WPs/WP modelling, ERA)

Assessment under Art. 141(1)(i)

- Use **already available** data
- **MAH consent** required

Scientific advice

- One report per combination
- Clear scope
- Goal: **one assessment/year**

Outcome

- **General** and **unambiguous** conclusions
- Lack of data will prevent recommending dosage changes

Project limitations



Assessment approach must be flexible and focus on the possibilities with the (limited) data and resources available

Stakeholders' interaction

Stakeholder interaction

is essential, both during the preparation phase and development of each CVMP scientific advice

Useful data from all MAHs

including results of modelling, and proposals for dosages or withdrawal periods

Focus group meeting

with concerned MAHs to anticipate and solve concerns

Consultation with concerned MAHs

to provide existing data for assessment and respond to CVMP questions

Open consultation

on draft scientific advice to allow academia to provide relevant data for scientific assessment

The involvement of the pharmaceutical industry is crucial

Phasing of activities



Thank you for your attention